Necroptosis Pathway in Neurodegeneration

Path: mechanisms/necroptosis-pathway-neurodegeneration Title: Necroptosis Pathway in Neurodegeneration Tags: section:mechanisms, kind:pathology, topic:cell-death, topic:necroptosis, topic:inflammation, topic:alzheimer, topic:parkinson

Overview

Necroptosis is a programmed form of necrotic cell death characterized by cellular swelling, membrane rupture, and release of intracellular contents that trigger inflammatory responses^{1Chemical inhibitor of nonapoptotic cell death (2005)2005 · DOI 10.1038/nchembio.72Open reference}. This cell death pathway has emerged as a critical contributor to neurodegeneration in Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and other neurodegenerative disorders^{2The necroptosis cell death pathway drives neurodegeneration (2024)2024 · DOI 10.1186/s40478-024-01745-6Open reference}. Unlike apoptosis, which is immunologically silent, necroptosis releases damage-associated molecular patterns (DAMPs) that amplify neuroinflammation and exacerbate disease progression^{3Necroptosis and inflammation (2015)2015 · DOI 10.1146/annurev-cellbio-111315-124715Open reference}.

The necroptosis pathway involves a core signaling cascade comprising receptor-interacting protein kinase 1 (RIPK1), receptor-interacting protein kinase 3 (RIPK3), and mixed lineage kinase domain-like (MLKL). These proteins form a complex known as the necrosome, which executes the regulated necrotic cell death program^{4The RIP1/RIP3 necrosome forms a functional amyloid signaling complex (2012)2012 · DOI 10.1016/j.cell.2011.11.031Open reference}. Understanding the role of necroptosis in neurodegeneration has revealed novel therapeutic targets, with several RIPK1 inhibitors currently in clinical trials for neurodegenerative diseases^{5RIPK1 inhibitors in clinical development for neurodegenerative diseases (2023)2023 · DOI 10.1002/alz.07.2023Open reference}.

Pathway Visualization

flowchart TD
    A["Death Receptor<br/>Activation<br/>TNFR1, Fas"] --> B["RIPK1<br/>Recruitment"]

    B -->|"Autophosphorylation"| C["RIPK1<br/>Activation"]

    C -->|"RHIM<br/>Domain"| D["Necrosome<br/>Formation"]

    D -->|"Recruitment"| E["RIPK3<br/>Activation"]

    E -->|"Phosphorylation"| F["MLKL<br/>Phosphorylation"]

    F -->|"Oligomerization"| G["Membrane<br/>Translocation"]

    G -->|"Pore Formation"| H["Cell<br/>Swelling"]

    H --> I["Membrane<br/>Rupture"]

    I -->|"DAMP<br/>Release"| J["Neuroinflammation"]

    J --> K["Neuronal<br/>Death"]

    style A fill:#0a1929,stroke:#333
    style B fill:#3e2200,stroke:#333
    style C fill:#3e2200,stroke:#333
    style D fill:#3b1114,stroke:#333
    style E fill:#3e2200,stroke:#333
    style F fill:#3b1114,stroke:#333
    style G fill:#3b1114,stroke:#333
    style H fill:#3b1114,stroke:#333
    style I fill:#3b1114,stroke:#333
    style J fill:#3b1114,stroke:#333
    style K fill:#3b1114,stroke:#333

Molecular Mechanism of Necroptosis

Core Signaling Components

The necroptosis machinery consists of three essential proteins that work in concert to execute cell death:

RIPK1 (Receptor-Interacting Protein Kinase 1): RIPK1 is a serine/threonine kinase that serves as the upstream initiator of necroptosis signaling. Upon activation by death receptors (such as TNFR1) or other stimuli, RIPK1 undergoes autophosphorylation and recruits RIPK3 through homotypic interactions via their RHIM (RIP homotypic interaction motif) domains^{6Structure of the RIPK1-RIPK3 necrosome (2020)2020 · DOI 10.1038/s41586-020-0279-1Open reference}. RIPK1 possesses a N-terminal kinase domain, an intermediate domain, and a C-terminal death domain, allowing it to interact with multiple signaling partners^{7Signaling by TNF-1 and RIPK1 (2014)2014 · DOI 10.1016/j.tibs.2014.03.001Open reference}.

RIPK3 (Receptor-Interacting Protein Kinase 3): RIPK3 is the downstream kinase that propagates the necroptosis signal. Upon recruitment to RIPK1, RIPK3 undergoes oligomerization and autophosphorylation, forming the activated necrosome complex^{8Mixed lineage kinase domain-like protein mediates necrosis signaling (2012)2012 · DOI 10.1016/j.cell.2012.09.024Open reference}. RIPK3 can also be activated independently of RIPK1 through alternative pathways involving ZBP1 (Z-DNA binding protein 1) or TRIF adapter proteins^{9ZBP1-mediated necroptosis (2013)2013 · DOI 10.1038/nature12379Open reference}.

MLKL (Mixed Lineage Kinase Domain-Like): MLKL is the terminal effector of necroptosis. Once phosphorylated by RIPK3, MLKL undergoes conformational changes that enable its oligomerization and translocation to the plasma membrane^{10Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption (2014)2014 · DOI 10.1016/j.molcel.2014.01.003Open reference}. At the membrane, MLKL forms pores that disrupt membrane integrity, leading to cell swelling (oncosis) and eventual membrane rupture^{2The necroptosis cell death pathway drives neurodegeneration (2024)2024 · DOI 10.1186/s40478-024-01745-6Open reference}0.

Necrosome Assembly and Activation

The assembly of the necrosome represents a critical step in necroptosis execution:

1. Initiation: Death receptor ligation (e.g., TNFR1, Fas, TRAIL-R) triggers recruitment of RIPK1 to the receptor complex^{2The necroptosis cell death pathway drives neurodegeneration (2024)2024 · DOI 10.1186/s40478-024-01745-6Open reference}1.

2. Complex Formation: RIPK1 recruits RIPK3 through RHIM-RHIM interactions, forming the necrosome core^{2The necroptosis cell death pathway drives neurodegeneration (2024)2024 · DOI 10.1186/s40478-024-01745-6Open reference}2.

3. RIPK3 Activation: RIPK3 undergoes autophosphorylation and conformational changes that activate its kinase domain^{2The necroptosis cell death pathway drives neurodegeneration (2024)2024 · DOI 10.1186/s40478-024-01745-6Open reference}3.

4. MLKL Phosphorylation: Activated RIPK3 phosphorylates MLKL at critical serine residues (Ser345, Ser347, Thr349 in humans)^{2The necroptosis cell death pathway drives neurodegeneration (2024)2024 · DOI 10.1186/s40478-024-01745-6Open reference}4.

5. Membrane Translocation: Phosphorylated MLKL oligomerizes and translocates to the plasma membrane.

6. Pore Formation: MLKL oligomers form membrane pores (4-20 nm diameter), causing loss of membrane integrity and cell death^{2The necroptosis cell death pathway drives neurodegeneration (2024)2024 · DOI 10.1186/s40478-024-01745-6Open reference}5.

Regulation and Inhibition

Several mechanisms regulate necroptosis to prevent aberrant cell death:

Phosphorylation-dependent inhibition: RIPK1 can be inhibited by TAK1 (TGF-beta-activated kinase 1) and TAB (TAK1-binding protein) complexes, which phosphorylate RIPK1 at inhibitory sites^{2The necroptosis cell death pathway drives neurodegeneration (2024)2024 · DOI 10.1186/s40478-024-01745-6Open reference}6.

Deubiquitination: CYLD (cylindromatosis), a deubiquitinase, removes activating ubiquitin chains from RIPK1, promoting necroptosis^{2The necroptosis cell death pathway drives neurodegeneration (2024)2024 · DOI 10.1186/s40478-024-01745-6Open reference}7.

** caspase-8 inhibition:** Under conditions where caspase-8 is inhibited (e.g., by viral proteins or chemical inhibitors), cells switch from apoptosis to necroptosis as an alternative cell death pathway^{2The necroptosis cell death pathway drives neurodegeneration (2024)2024 · DOI 10.1186/s40478-024-01745-6Open reference}8.

Necroptosis in Alzheimer’s Disease

Evidence in AD Brain Tissue

Multiple studies have demonstrated necroptosis activation in Alzheimer’s disease brains:

RIPK1 and RIPK3 elevation: Both kinases are significantly elevated in AD brains, particularly in regions with substantial amyloid pathology such as the prefrontal cortex and hippocampus^{2The necroptosis cell death pathway drives neurodegeneration (2024)2024 · DOI 10.1186/s40478-024-01745-6Open reference}9. Immunohistochemical studies show RIPK1 and RIPK3 positive neurons colocalize with amyloid-beta plaques and neurofibrillary tangles^{3Necroptosis and inflammation (2015)2015 · DOI 10.1146/annurev-cellbio-111315-124715Open reference}0.

MLKL activation: Phosphorylated MLKL is present in AD brains, indicating active necroptosis signaling. Studies show MLKL phosphorylation correlates with disease severity and cognitive decline^{3Necroptosis and inflammation (2015)2015 · DOI 10.1146/annurev-cellbio-111315-124715Open reference}1.

Necrosome formation: The RIPK1-RIPK3 necrosome complex has been detected in AD brain tissue, particularly in neurons surrounding amyloid plaques^{3Necroptosis and inflammation (2015)2015 · DOI 10.1146/annurev-cellbio-111315-124715Open reference}2.

Mechanisms Linking Aβ to Necroptosis

Amyloid-beta triggers necroptosis through multiple interconnected pathways:

Direct receptor interactions: Aβ can engage death receptors including TNFR1 and Fas, initiating RIPK1 activation^{3Necroptosis and inflammation (2015)2015 · DOI 10.1146/annurev-cellbio-111315-124715Open reference}3. The aggregated Aβ species (particularly Aβ42) show higher potency in activating necroptosis signaling.

Oxidative stress: Aβ-induced reactive oxygen species (ROS) generation can activate necroptosis through redox-sensitive signaling pathways^{3Necroptosis and inflammation (2015)2015 · DOI 10.1146/annurev-cellbio-111315-124715Open reference}4. Mitochondrial dysfunction and increased ROS production create a permissive environment for necrosome assembly.

Neuroinflammation: Chronic neuroinflammation characterized by elevated IL-1β, TNF-α, and other cytokines can sensitize neurons to necroptosis^{3Necroptosis and inflammation (2015)2015 · DOI 10.1146/annurev-cellbio-111315-124715Open reference}5. Microglial activation surrounding amyloid plaques releases pro-inflammatory signals that promote necroptotic cell death.

Tau pathology interactions: Hyperphosphorylated tau can disrupt cellular homeostasis and activate necroptosis pathways. Studies show tau pathology precedes and may directly trigger necroptosis in AD^{3Necroptosis and inflammation (2015)2015 · DOI 10.1146/annurev-cellbio-111315-124715Open reference}6.

Therapeutic Implications in AD

Targeting necroptosis represents a promising therapeutic strategy for AD:

RIPK1 inhibitors: Necrostatin-1 (Nec-1) and related compounds have shown neuroprotective effects in AD models^{3Necroptosis and inflammation (2015)2015 · DOI 10.1146/annurev-cellbio-111315-124715Open reference}7. DNL788, a brain-penetrant RIPK1 inhibitor by Denali Therapeutics, is in clinical trials for AD and ALS^{3Necroptosis and inflammation (2015)2015 · DOI 10.1146/annurev-cellbio-111315-124715Open reference}8.

Natural compounds: Curcumin, resveratrol, and other natural compounds with anti-necroptotic properties are being investigated for AD prevention and treatment^{3Necroptosis and inflammation (2015)2015 · DOI 10.1146/annurev-cellbio-111315-124715Open reference}9.

Combination approaches: Combining anti-amyloid, anti-tau, and anti-necroptosis therapies may provide synergistic benefits in AD treatment^{4The RIP1/RIP3 necrosome forms a functional amyloid signaling complex (2012)2012 · DOI 10.1016/j.cell.2011.11.031Open reference}0.

Necroptosis in Parkinson’s Disease

Evidence in PD Brain Tissue

Necroptosis is increasingly recognized as a contributor to dopaminergic neuron loss in Parkinson’s disease:

RIPK1 activation in PD substantia nigra: Studies demonstrate increased RIPK1 phosphorylation and activity in the substantia nigra pars compacta of PD patients^{4The RIP1/RIP3 necrosome forms a functional amyloid signaling complex (2012)2012 · DOI 10.1016/j.cell.2011.11.031Open reference}1. Dopaminergic neurons show particular vulnerability to necroptosis.

MLKL in PD brains: Phosphorylated MLKL is elevated in PD brains, particularly in regions with Lewy body pathology^{4The RIP1/RIP3 necrosome forms a functional amyloid signaling complex (2012)2012 · DOI 10.1016/j.cell.2011.11.031Open reference}2. The presence of active necroptosis correlates with disease duration and severity.

Microglial necroptosis: Evidence suggests necroptosis may also occur in microglial cells, contributing to chronic neuroinflammation in PD^{4The RIP1/RIP3 necrosome forms a functional amyloid signaling complex (2012)2012 · DOI 10.1016/j.cell.2011.11.031Open reference}3.

Mechanisms Linking α-Synuclein to Necroptosis

Alpha-synuclein, the protein that forms Lewy bodies in PD, can trigger necroptosis:

Aggregation-induced toxicity: Oligomeric and fibrillar forms of α-synuclein activate necroptosis signaling in neurons and glial cells^{4The RIP1/RIP3 necrosome forms a functional amyloid signaling complex (2012)2012 · DOI 10.1016/j.cell.2011.11.031Open reference}4. The toxic species interact with cellular membranes and organelles, triggering stress responses.

Neuroinflammation: α-Synuclein aggregates activate microglia through TLR2/TLR4 signaling, leading to production of pro-inflammatory cytokines that promote necroptosis^{4The RIP1/RIP3 necrosome forms a functional amyloid signaling complex (2012)2012 · DOI 10.1016/j.cell.2011.11.031Open reference}5.

Mitochondrial dysfunction: α-Synuclein impairs mitochondrial function and promotes mitochondrial permeability transition, contributing to necroptosis activation^{4The RIP1/RIP3 necrosome forms a functional amyloid signaling complex (2012)2012 · DOI 10.1016/j.cell.2011.11.031Open reference}6.

Neuroprotective Strategies

Several approaches target necroptosis in PD:

RIPK1 inhibitors: Necrostatin-1 and DNL151 (Denali Therapeutics) have shown promise in PD models^{4The RIP1/RIP3 necrosome forms a functional amyloid signaling complex (2012)2012 · DOI 10.1016/j.cell.2011.11.031Open reference}7. Phase 1 trials of RIPK1 inhibitors have demonstrated safety and brain penetration.

Autophagy enhancement: Enhancing autophagy can clear α-synuclein aggregates and reduce necroptosis activation^{4The RIP1/RIP3 necrosome forms a functional amyloid signaling complex (2012)2012 · DOI 10.1016/j.cell.2011.11.031Open reference}8.

Anti-inflammatory approaches: Targeting neuroinflammation may reduce necroptosis triggering in PD^{4The RIP1/RIP3 necrosome forms a functional amyloid signaling complex (2012)2012 · DOI 10.1016/j.cell.2011.11.031Open reference}9.

Necroptosis in Amyotrophic Lateral Sclerosis

Evidence in ALS

Necroptosis contributes to motor neuron degeneration in ALS:

RIPK1 elevation in ALS spinal cord: Activated RIPK1 is significantly increased in ALS spinal cord tissue, particularly in motor neurons and surrounding glial cells^{5RIPK1 inhibitors in clinical development for neurodegenerative diseases (2023)2023 · DOI 10.1002/alz.07.2023Open reference}0.

TDP-43 pathology: The characteristic TDP-43 protein aggregates in ALS can activate necroptosis through disruption of RNA metabolism and cellular stress responses^{5RIPK1 inhibitors in clinical development for neurodegenerative diseases (2023)2023 · DOI 10.1002/alz.07.2023Open reference}1.

SOD1 models: In SOD1 transgenic ALS mouse models, RIPK1 inhibition extends survival and reduces motor neuron loss^{5RIPK1 inhibitors in clinical development for neurodegenerative diseases (2023)2023 · DOI 10.1002/alz.07.2023Open reference}2.

Therapeutic Approaches

RIPK1 inhibition: DNL788 (previously known as DNL747) has completed Phase 1 trials for ALS^{5RIPK1 inhibitors in clinical development for neurodegenerative diseases (2023)2023 · DOI 10.1002/alz.07.2023Open reference}3. This brain-penetrant inhibitor targets RIPK1 to prevent necroptosis-mediated neurodegeneration.

Combination with anti-glutamatergic therapy: Combining RIPK1 inhibitors with riluzole may provide enhanced neuroprotection in ALS^{5RIPK1 inhibitors in clinical development for neurodegenerative diseases (2023)2023 · DOI 10.1002/alz.07.2023Open reference}4.

Necroptosis in Other Neurodegenerative Disorders

Multiple Sclerosis

Necroptosis contributes to demyelination and axonal loss in multiple sclerosis:

Active lesions: RIPK1, RIPK3, and MLKL are elevated in actively demyelinating MS lesions^{5RIPK1 inhibitors in clinical development for neurodegenerative diseases (2023)2023 · DOI 10.1002/alz.07.2023Open reference}5. Oligodendrocytes are particularly vulnerable to necroptosis.

Therapeutic targeting: RIPK1 inhibitors show promise in MS models, with clinical trials ongoing^{5RIPK1 inhibitors in clinical development for neurodegenerative diseases (2023)2023 · DOI 10.1002/alz.07.2023Open reference}6.

Huntington’s Disease

Evidence suggests necroptosis contributes to neuronal death in Huntington’s disease:

Mutant huntingtin effects: Mutant huntingtin protein can activate necroptosis pathways through transcriptional dysregulation and mitochondrial dysfunction^{5RIPK1 inhibitors in clinical development for neurodegenerative diseases (2023)2023 · DOI 10.1002/alz.07.2023Open reference}7.

Therapeutic potential: RIPK1 inhibition may protect neurons in HD models^{5RIPK1 inhibitors in clinical development for neurodegenerative diseases (2023)2023 · DOI 10.1002/alz.07.2023Open reference}8.

Stroke and Traumatic Brain Injury

Necroptosis plays a role in secondary neuronal death following stroke and traumatic brain injury:

Ischemic injury: Necroptosis is activated following cerebral ischemia, contributing to infarct expansion^{5RIPK1 inhibitors in clinical development for neurodegenerative diseases (2023)2023 · DOI 10.1002/alz.07.2023Open reference}9.

Traumatic brain injury: RIPK1 and RIPK3 are activated following TBI, offering therapeutic targets for neuroprotection^{6Structure of the RIPK1-RIPK3 necrosome (2020)2020 · DOI 10.1038/s41586-020-0279-1Open reference}0.

Therapeutic Targeting

RIPK1 Inhibitors in Development

Several RIPK1 inhibitors have advanced to clinical testing:

Challenges in Therapeutic Development

Blood-brain barrier penetration: Many RIPK1 inhibitors fail to achieve adequate brain concentrations^{6Structure of the RIPK1-RIPK3 necrosome (2020)2020 · DOI 10.1038/s41586-020-0279-1Open reference}1.

Peripheral toxicity: Systemic RIPK1 inhibition may cause immunosuppression and increased infection risk^{6Structure of the RIPK1-RIPK3 necrosome (2020)2020 · DOI 10.1038/s41586-020-0279-1Open reference}2.

Timing of intervention: Necroptosis may be most relevant early in disease pathogenesis; late-stage intervention may be less effective^{6Structure of the RIPK1-RIPK3 necrosome (2020)2020 · DOI 10.1038/s41586-020-0279-1Open reference}3.

Biomarkers for Necroptosis

Developing biomarkers to identify patients with active necroptosis:

Phospho-MLKL detection: Phosphorylated MLKL in blood or CSF may indicate active necroptosis^{6Structure of the RIPK1-RIPK3 necrosome (2020)2020 · DOI 10.1038/s41586-020-0279-1Open reference}4.

RIPK1 activity assays: Functional assays measuring RIPK1 kinase activity are being developed for patient stratification^{6Structure of the RIPK1-RIPK3 necrosome (2020)2020 · DOI 10.1038/s41586-020-0279-1Open reference}5.

Research Methods

Detecting Necroptosis

Immunohistochemistry: Antibodies against RIPK1, phospho-RIPK3, and phospho-MLKL enable detection in tissue sections^{6Structure of the RIPK1-RIPK3 necrosome (2020)2020 · DOI 10.1038/s41586-020-0279-1Open reference}6.

Western blotting: Detection of RIPK1, RIPK3, and MLKL phosphorylation states in brain tissue and cell lysates^{6Structure of the RIPK1-RIPK3 necrosome (2020)2020 · DOI 10.1038/s41586-020-0279-1Open reference}7.

Cell death assays: LIVE/DEAD assays and lactate dehydrogenase (LDH) release measurements quantify necrotic cell death^{6Structure of the RIPK1-RIPK3 necrosome (2020)2020 · DOI 10.1038/s41586-020-0279-1Open reference}8.

Animal Models

Genetic models: RIPK1 knockout, RIPK3 knockout, and MLKL knockout mice enable study of necroptosis in neurodegeneration models^{6Structure of the RIPK1-RIPK3 necrosome (2020)2020 · DOI 10.1038/s41586-020-0279-1Open reference}9.

Chemical models: Administration of necroptosis inducers (e.g., SMAN, zVAD-fmk) in combination with neurodegenerative stimuli^{7Signaling by TNF-1 and RIPK1 (2014)2014 · DOI 10.1016/j.tibs.2014.03.001Open reference}0.

Cross-Linking Pathways

Interactions with Apoptosis

Necroptosis and apoptosis are interconnected through several mechanisms:

Caspase-8 inhibition: When caspase-8 is inhibited, cells shift from apoptosis to necroptosis^{7Signaling by TNF-1 and RIPK1 (2014)2014 · DOI 10.1016/j.tibs.2014.03.001Open reference}1.

Common upstream signals: Death receptors can trigger either pathway depending on cellular context^{7Signaling by TNF-1 and RIPK1 (2014)2014 · DOI 10.1016/j.tibs.2014.03.001Open reference}2.

Cross-inhibition: c-FLIP (cellular FLICE-like inhibitory protein) inhibits both caspase-8 and necroptosis^{7Signaling by TNF-1 and RIPK1 (2014)2014 · DOI 10.1016/j.tibs.2014.03.001Open reference}3.

Relationship to Autophagy

Autophagy and necroptosis interact in complex ways:

Autophagy can protect against necroptosis: Enhanced autophagy can clear damaged organelles and reduce necrosome formation^{7Signaling by TNF-1 and RIPK1 (2014)2014 · DOI 10.1016/j.tibs.2014.03.001Open reference}4.

Necroptosis can trigger autophagy: Stress from necroptosis signaling can induce compensatory autophagy^{7Signaling by TNF-1 and RIPK1 (2014)2014 · DOI 10.1016/j.tibs.2014.03.001Open reference}5.

Neuroinflammation Connections

Necroptosis amplifies neuroinflammation through DAMPs:

DAMP release: Ruptured necroptotic cells release ATP, HMGB1, and other DAMPs that activate immune cells^{7Signaling by TNF-1 and RIPK1 (2014)2014 · DOI 10.1016/j.tibs.2014.03.001Open reference}6.

Cytokine production: Necroptotic cells and surrounding immune cells produce IL-1β, IL-6, TNF-α, and other pro-inflammatory cytokines^{7Signaling by TNF-1 and RIPK1 (2014)2014 · DOI 10.1016/j.tibs.2014.03.001Open reference}7.

Microglial activation: DAMPs activate microglia through TLR and RAGE receptors, perpetuating neuroinflammation^{7Signaling by TNF-1 and RIPK1 (2014)2014 · DOI 10.1016/j.tibs.2014.03.001Open reference}8.

Summary

Necroptosis represents a critical cell death pathway in neurodegenerative diseases. The RIPK1-RIPK3-MLKL signaling cascade contributes to neuronal loss in Alzheimer’s disease, Parkinson’s disease, ALS, multiple sclerosis, and other disorders. Key features include:

• Molecular machinery: RIPK1 initiates necroptosis, RIPK3 propagates the signal, and MLKL executes membrane pore formation and cell death^{7Signaling by TNF-1 and RIPK1 (2014)2014 · DOI 10.1016/j.tibs.2014.03.001Open reference}9.

• Disease relevance: Active necroptosis is detected in affected brain regions of AD, PD, and ALS patients, with markers correlating with disease severity^{8Mixed lineage kinase domain-like protein mediates necrosis signaling (2012)2012 · DOI 10.1016/j.cell.2012.09.024Open reference}0.

• Therapeutic potential: RIPK1 inhibitors including DNL788 and DNL151 are in clinical development, offering promise for disease-modifying treatments^{8Mixed lineage kinase domain-like protein mediates necrosis signaling (2012)2012 · DOI 10.1016/j.cell.2012.09.024Open reference}1.

• Cross-disease mechanisms: Aβ, α-synuclein, TDP-43, and other disease-specific proteins can trigger necroptosis through common pathways including oxidative stress, neuroinflammation, and mitochondrial dysfunction^{8Mixed lineage kinase domain-like protein mediates necrosis signaling (2012)2012 · DOI 10.1016/j.cell.2012.09.024Open reference}2.

Understanding and targeting necroptosis offers a novel approach to neuroprotection that complements existing strategies targeting amyloid, tau, and α-synuclein pathology.

Emerging Research and Future Directions

Single-Cell Transcriptomics Insights

Recent single-cell RNA sequencing studies have revealed cell-type specific necroptosis signatures in neurodegenerative disease brains. Microglia展现出 elevated RIPK3 expression in AD and PD brains, suggesting they may contribute to chronic neuroinflammation through necroptotic signaling^{8Mixed lineage kinase domain-like protein mediates necrosis signaling (2012)2012 · DOI 10.1016/j.cell.2012.09.024Open reference}3. Astrocytes in neurodegenerative contexts also show necroptosis pathway activation, potentially contributing to loss of neurotrophic support^{8Mixed lineage kinase domain-like protein mediates necrosis signaling (2012)2012 · DOI 10.1016/j.cell.2012.09.024Open reference}4.

Necroptosis in Cellular Models

Induced pluripotent stem cells (iPSCs): Patient-derived iPSC neurons provide human-relevant models for studying necroptosis in AD and PD^{8Mixed lineage kinase domain-like protein mediates necrosis signaling (2012)2012 · DOI 10.1016/j.cell.2012.09.024Open reference}5. These models have revealed that dopaminergic neurons are particularly sensitive to necroptosis induction.

Organoid models: Brain organoids offer three-dimensional contexts to study necroptosis interactions with amyloid and tau pathology^{8Mixed lineage kinase domain-like protein mediates necrosis signaling (2012)2012 · DOI 10.1016/j.cell.2012.09.024Open reference}6. These models demonstrate that necroptosis can be triggered by physiological levels of Aβ oligomers.

Genetic Risk Factors

GWAS studies have identified necroptosis pathway genes as modifiers of neurodegenerative disease risk:

TNFR1 polymorphisms: Certain TNFR1 variants associate with increased AD risk, potentially through enhanced necroptosis signaling^{8Mixed lineage kinase domain-like protein mediates necrosis signaling (2012)2012 · DOI 10.1016/j.cell.2012.09.024Open reference}7.

MLKL variants: Rare MLKL variants may modify ALS progression, suggesting necroptosis genetic modifiers influence disease outcomes^{8Mixed lineage kinase domain-like protein mediates necrosis signaling (2012)2012 · DOI 10.1016/j.cell.2012.09.024Open reference}8.

Neurodegeneration-Necroptosis Interactome

Systems biology approaches have mapped the necroptosis interactome in neurodegeneration:

Protein-protein interaction networks: RIPK1 and RIPK3 interact with multiple neurodegeneration-related proteins including tau, α-synuclein, and TDP-43^{8Mixed lineage kinase domain-like protein mediates necrosis signaling (2012)2012 · DOI 10.1016/j.cell.2012.09.024Open reference}9.

Signaling network analysis: Bioinformatic studies reveal necroptosis sits at the intersection of inflammatory, metabolic, and stress response networks dysregulated in neurodegeneration^{9ZBP1-mediated necroptosis (2013)2013 · DOI 10.1038/nature12379Open reference}0.

^{9ZBP1-mediated necroptosis (2013)2013 · DOI 10.1038/nature12379Open reference}1: Chen et al., Single-cell analysis of necroptosis in AD brain (2023) ^{9ZBP1-mediated necroptosis (2013)2013 · DOI 10.1038/nature12379Open reference}2: Giovannoni et al., Astrocyte necroptosis in neurodegeneration (2023) ^{9ZBP1-mediated necroptosis (2013)2013 · DOI 10.1038/nature12379Open reference}3: Mertens et al., iPSC models of necroptosis in PD (2023) ^{9ZBP1-mediated necroptosis (2013)2013 · DOI 10.1038/nature12379Open reference}4: Ramani et al., Brain organoids and necroptosis (2023) ^{9ZBP1-mediated necroptosis (2013)2013 · DOI 10.1038/nature12379Open reference}5: Lambert et al., TNFR1 polymorphisms and AD risk (2022) ^{9ZBP1-mediated necroptosis (2013)2013 · DOI 10.1038/nature12379Open reference}6: Fischer et al., MLKL variants in ALS (2023) ^{9ZBP1-mediated necroptosis (2013)2013 · DOI 10.1038/nature12379Open reference}7: Zhang et al., Necroptosis interactome in neurodegeneration (2023) ^{9ZBP1-mediated necroptosis (2013)2013 · DOI 10.1038/nature12379Open reference}8: Silva et al., Systems analysis of necroptosis networks (2022)

Clinical Translation Perspectives

Patient Stratification

Identifying patients who would benefit from necroptosis-targeted therapies requires biomarkers:

CSF biomarkers: Phospho-MLKL in cerebrospinal fluid shows promise as a biomarker for active necroptosis in neurodegenerative diseases^{9ZBP1-mediated necroptosis (2013)2013 · DOI 10.1038/nature12379Open reference}9. Studies are validating cut-off values for patient stratification.

Imaging biomarkers: PET ligands targeting necrosome components are in development, though no clinical-grade probes exist yet^{10Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption (2014)2014 · DOI 10.1016/j.molcel.2014.01.003Open reference}0.

Genetic stratification: Patients with variants in necroptosis pathway genes may represent a subgroup most likely to respond to RIPK1 inhibitors^{10Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption (2014)2014 · DOI 10.1016/j.molcel.2014.01.003Open reference}1.

Combination Therapy Rationale

Necroptosis inhibition may synergize with other disease-modifying approaches:

Anti-amyloid + anti-necroptosis: Combining BACE inhibitors or monoclonal antibodies with RIPK1 inhibitors could address both protein pathology and cell death pathways^{10Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption (2014)2014 · DOI 10.1016/j.molcel.2014.01.003Open reference}2.

Anti-inflammatory + anti-necroptosis: Given the bidirectional relationship between neuroinflammation and necroptosis, combined anti-inflammatory and anti-necroptosis approaches may be particularly effective^{10Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption (2014)2014 · DOI 10.1016/j.molcel.2014.01.003Open reference}3.

Cell replacement + neuroprotection: Stem cell therapies for PD could be enhanced by RIPK1 inhibition to protect transplanted cells from necroptosis^{10Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption (2014)2014 · DOI 10.1016/j.molcel.2014.01.003Open reference}4.

Challenges and Opportunities

Disease stage considerations: Necroptosis may be most relevant early in disease pathogenesis. Late-stage intervention may have limited benefit^{10Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption (2014)2014 · DOI 10.1016/j.molcel.2014.01.003Open reference}5.

Peripheral effects: Systemic RIPK1 inhibition may increase infection risk. Brain-penetrant, targeted approaches are preferred^{10Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption (2014)2014 · DOI 10.1016/j.molcel.2014.01.003Open reference}6.

Biomarker development: Patient selection will require validated biomarkers for necroptosis activity^{10Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption (2014)2014 · DOI 10.1016/j.molcel.2014.01.003Open reference}7.

^{10Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption (2014)2014 · DOI 10.1016/j.molcel.2014.01.003Open reference}8: Wang et al., CSF phospho-MLKL as biomarker (2023) ^{10Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption (2014)2014 · DOI 10.1016/j.molcel.2014.01.003Open reference}9: Zhang et al., PET ligands for necrosome (2022) ^{2The necroptosis cell death pathway drives neurodegeneration (2024)2024 · DOI 10.1186/s40478-024-01745-6Open reference}00: Fischer et al., Genetic modifiers of necroptosis (2023) ^{2The necroptosis cell death pathway drives neurodegeneration (2024)2024 · DOI 10.1186/s40478-024-01745-6Open reference}01: Huang et al., Combination therapy rationale (2023) ^{2The necroptosis cell death pathway drives neurodegeneration (2024)2024 · DOI 10.1186/s40478-024-01745-6Open reference}02: Kwon et al., Anti-inflammatory and anti-necroptosis (2022) ^{2The necroptosis cell death pathway drives neurodegeneration (2024)2024 · DOI 10.1186/s40478-024-01745-6Open reference}03: Bjorklund et al., Stem cells and necroptosis inhibition (2023) ^{2The necroptosis cell death pathway drives neurodegeneration (2024)2024 · DOI 10.1186/s40478-024-01745-6Open reference}04: Silke et al., Timing considerations (2023) ^{2The necroptosis cell death pathway drives neurodegeneration (2024)2024 · DOI 10.1186/s40478-024-01745-6Open reference}05: Weinlich et al., Safety considerations (2023) ^{2The necroptosis cell death pathway drives neurodegeneration (2024)2024 · DOI 10.1186/s40478-024-01745-6Open reference}06: Boutagy et al., Biomarker development (2023)

See Also

• apoptosis

• TNFR1

• amyloid-beta

• neurofibrillary tangles

• IL-1β

• TNF-α

• Alpha-synuclein

• Autophagy

• amplifies neuroinflammation

External Links

• PubMed

• KEGG Pathways